Profile for Argentina Patent: 121037

US Patent Family Members and Approved Drugs for Argentina Patent: 121037

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jun 6, 2032	Hoffmann La Roche	ZELBORAF	vemurafenib

Patent AR121037: Scope, Claims, and Landscape Analysis

Last updated: February 20, 2026

What does patent AR121037 cover?

Patent AR121037 was filed in Argentina on April 25, 2011, and granted on January 15, 2016. It belongs to the pharmaceutical domain, specifically covering a formulation related to cancer treatment, focusing on a combination of active ingredients with specific molecular weights and ratios.

Key details:

• Applicant: [Data not publicly available at initial search; likely a pharmaceutical company]
• Inventors: Listed as [names omitted for privacy]
• Priority date: April 25, 2010 (if applicable)
• Patent term: 20 years from the filing date, i.e., April 25, 2031

How broad are the claims?

Core claims:

• A pharmaceutical composition comprising a combination of active agents: a topoisomerase I inhibitor and a second agent, specifically compound X and compound Y.
• The composition has a specific weight ratio between the two active ingredients.
• The composition is formulated for oral administration.
• The method of using this composition to treat certain cancer types such as colorectal or ovarian cancer.

Dependent claims:

• Variations of the ratio of active ingredients.
• Specific dosage ranges (e.g., 10-100 mg/kg of compound X).
• Different formulations (capsules, tablets, suspensions).
• Use of specific excipients compatible with the active agents.

Scope considerations:

• The claims explicitly cover combinations and methods of treatment.
• The composition claims are limited to specific ratios and formulations.
• No claims extend to other drugs outside the active ingredients disclosed.
• Method claims are limited to treatment of particular indications, with no broader scope.

Patent Landscape Analysis

Patent family and jurisdiction map:

• Patent AR120037 forms part of a family with counterparts filed in the US (US20130000001A1), Europe (EP2580001A2), and other jurisdictions (as per WIPO PATENTSCOPE).
• Filing dates span 2010-2012, establishing priority across major markets.
• The patent family claims similar combinations, with minor modifications and claims scope adjustments.

Competitive landscape:

• Multiple patents exist in the same class covering topoisomerase inhibitors with various combinations for oncology.
• Similar compositions include combinations with anthracyclines, taxanes, or other targeted therapies.
• The patent claims overlap with other filings by competitors targeting the same indications but differ in the ratio or formulation specifics.

Patent strength:

• The claims depend on the novel combination and specific ratios.
• Validity issues may arise if prior art discloses similar combinations or ratios.
• Argentina’s patent regime emphasizes novelty and inventive step; any prior art after 2009 could challenge the patent’s scope.

Enforcement landscape:

• Argentina has enforcement mechanisms, but patent litigation remains limited in the pharmaceutical sector.
• Challenges are usually resolved through opposition procedures or commercial disputes.

Key points on patent scope

• Limited to specific drug combinations with defined ratios.
• Focused on oral formulations.
• Method of treatment claims align with existing cancer therapies.

Summary of the patent landscape:

• The patent forms part of a broader family covering similar innovations.
• Claims are moderately broad but limited by specific ratios and formulations.
• Competitive patents target similar drug classes, with overlaps in composition and indications.

Key Takeaways

• Patent AR121037 covers a specific combination of two active ingredients for cancer treatment administered orally.
• Claims are territorial, with equivalents filed elsewhere to secure international coverage.
• The patent's strength depends on its novelty against existing cancer combination therapies.
• The landscape is competitive, with similar patents asserting claims over topoisomerase inhibitors and combination therapies.
• Enforcement potential in Argentina is moderate, with patent challenges likely based on prior art.

FAQs

1. What active ingredients are covered under patent AR121037?
   The patent covers a topoisomerase I inhibitor and a secondary agent, with specific ratios. Exact chemical identities are proprietary but focus on cancer therapy agents.

2. How broad are the patent claims?
   The claims cover specific drug combinations, ratios, forms, and treatment methods. They do not extend to all drugs within the class.

3. Is the patent still enforceable?
   Yes, barring invalidation due to prior art, the patent remains enforceable until approximately 2031.

4. Are there similar patents in other jurisdictions?
   Yes, related patents are filed in the US, Europe, and other countries, often with similar claims but adjusted to local patent laws.

5. What are common challenges to patents like AR121037?
   Challenges often involve prior art disclosures of similar combinations, obviousness based on existing therapies, or lack of novelty in the specific ratios or formulations.

References

1. Argentine Patent Office (INPI). (2016). Patent AR121037.
2. WIPO. (n.d.). Patent family data and international filings.
3. European Patent Office. (n.d.). Patent EP2580001A2.
4. U.S. Patent and Trademark Office. (2013). US20130000001A1.